| 1.55 0.04 (2.65%) | 10-14 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 2.09 | 1-year : | 2.67 |
| Resists | First : | 1.79 | Second : | 2.28 |
| Pivot price | 1.39 |
|||
| Supports | First : | 1 | Second : | 0.83 |
| MAs | MA(5) : | 1.44 |
MA(20) : | 1.36  |
| MA(100) : | 1.94 |
MA(250) : | 2.17 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.2 |
| %K %D | K(14,3) : | 78.4 |
D(3) : | 74.3 |
| RSI | RSI(14): 50.9 |
|||
| 52-week | High : | 3.2 | Low : | 1 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ BCDA ] has closed Bollinger Bands are 56.8% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 3 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 1.58 - 1.59 | 1.59 - 1.59 |
| Low: | 1.39 - 1.4 | 1.4 - 1.4 |
| Close: | 1.54 - 1.55 | 1.55 - 1.56 |
BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases. Its lead therapeutic candidate is the CardiAMP Cell Therapy System for the treatment of heart failure and chronic myocardial ischemia; and allogeneic cell therapy for cardiac and pulmonary disease. The company is also developing allogeneic cells therapeutic platform, an investigational culture expanded bone marrow derived mesenchymal cell therapy, which is in Phase I/II trial for the treatment of ischemic systolic heart failure. In addition, it offers the Helix biotherapeutic delivery system that delivers therapeutics into the heart muscle with a penetrating helical needle from within the heart; and Morph deflectable guides and sheaths. The company is based in Sunnyvale, California.
Fri, 03 Oct 2025
BioCardia Regains Nasdaq Compliance, Secures Continued Listing - The Globe and Mail
Thu, 02 Oct 2025
Cardiovascular Therapeutics Developer BioCardia Successfully Maintains Nasdaq Capital Market Listing - Stock Titan
Tue, 23 Sep 2025
Altman Peter, president and CEO of BioCardia, buys $60000 in BCDA - Investing.com
Mon, 22 Sep 2025
178 Patient Trial Data: BioCardia's Breakthrough Cell Therapy for Heart Failure Advances in Japan - Stock Titan
Sat, 20 Sep 2025
Insiders' US$1.06m Investments In Red Following BioCardia's US$117k Dip In Market Value - simplywall.st
Thu, 18 Sep 2025
BioCardia’s Stock Dilemma: Opportunity or Risk? - StocksToTrade
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 11 (M) |
| Shares Float | 4 (M) |
| Held by Insiders | 18.3 (%) |
| Held by Institutions | 2.8 (%) |
| Shares Short | 199 (K) |
| Shares Short P.Month | 209 (K) |
| EPS | -1.68 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -0.35 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -222.3 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | -0.5 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -0.84 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -8 (M) |
| Levered Free Cash Flow | -5 (M) |
| PE Ratio | -0.93 |
| PEG Ratio | 0 |
| Price to Book value | -4.56 |
| Price to Sales | 0 |
| Price to Cash Flow | -1.95 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|